

Botanix receives additional patent allowance for Sofdra®

The patent is expected to add to existing patent protections against unauthorised commercial manufacturing of Sofdra's drug substance into May 2040

PHOENIX, AZ, UNITED STATES, July 13, 2026 /EINPresswire.com/ -- [Botanix](#) Pharmaceuticals Limited (ASX:BOT, "Botanix" or "the Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for US patent application Serial No. 17/611,158, "Crystalline Form of Sofpironium Bromide and Preparation Method Thereof." The application covers commercially relevant intellectual property protecting the drug substance underpinning Sofdra® (sofpironium), Botanix's FDA-approved treatment for primary axillary hyperhidrosis in adults and paediatric patients aged nine and older.



Primary axillary hyperhidrosis is a medical condition causing excessive underarm sweating that is not triggered by heat or exercise.

“

Strengthening the company's intellectual property estate around Sofdra® remained an important strategic priority...”

Dr Howie McKibbon, Chief Executive Officer of Botanix

The allowed claims relate to proprietary aspects of the sofpironium drug substance technology used in Sofdra®'s commercial manufacture. Once issued, the patent is expected to strengthen Botanix's intellectual property protection surrounding Sofdra® in the United States, protecting against unauthorized commercial manufacturing of the drug substance into May 2040.

The actual chemical entity itself (in this case, the crystalline form of sofpironium bromide), is generally considered the hardest to design around. That's why this type of patent is

highly valued by companies and investors alike.

Dr Howie McKibbon, Chief Executive Officer of Botanix, said strengthening the company's intellectual property estate around Sofdra® remained an important strategic priority, and that the Notice of Allowance further expanded its US patent portfolio, supporting the long-term commercial opportunity for Sofdra® out to 2040.

Having multiple issued patents providing protection to 2040 gives Botanix a long window of market exclusivity for Sofdra®, which supports long-term revenue, makes the asset more attractive for potential licensing or partnership deals, and reduces the risk profile for investors.

Botanix is committed to protecting the innovations underpinning its lead commercial product as it continues to build out its US dermatology offering.

Jane Morgan
Investor and Media Relations
+61 405 555 618

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/926238204>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.